John Leppert

Publications

• Diabetic Severity and Risk of Kidney Stone Disease. Weinberg AE, Patel CJ, Chertow GM, Leppert JT. Eur Urol. 2013
• Interobserver agreement of confocal laser endomicroscopy for bladder cancer. Chang TC, Liu JJ, Hsiao ST, Pan Y, Mach KE, Leppert JT, McKenney JK, Rouse RV, Liao JC. J Endourol. 2013; 27 (5): 598-603
• Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma. Kroeger N, Seligson DB, Klatte T, Rampersaud EN, Birkhäuser FD, Rao PN, Leppert JT, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Eur Urol. 2012; 61 (5): 888-95
• The use of mannitol in partial and live donor nephrectomy: an international survey. Cosentino M, Breda A, Sanguedolce F, Landman J, Stolzenburg JU, Verze P, Rassweiler J, Van Poppel H, Klingler HC, Janetschek G, Celia A, Kim FJ, Thalmann G, Nagele U, Mogorovich A, Bolenz C, Knoll T, Porpiglia F, Alvarez-Maestro M, Francesca F, Deho F, Eggener S, Abbou C, Meng MV, Aron M, Laguna P, Mladenov D, D'Addessi A, Bove P, Schiavina R, De Cobelli O, Merseburger AS, Dalpiaz O, D'Ancona FC, Polascik TJ, Muschter R, Leppert TJ, Villavicencio H. World J Urol. 2012
• Laparoendoscopic single-site porcine nephrectomy using a novel valveless trocar system. Leppert JT, Breda A, Harper JD, Schulam PG. J Endourol. 2011; 25 (1): 119-22
• Standardized linear port configuration to improve operative ergonomics in laparoscopic renal and adrenal surgery: experience with 1264 cases. Harper JD, Leppert JT, Breda A, Schulam PG. J Endourol. 2011; 25 (11): 1769-73
• Comparison of accuracy of 14-, 18- and 20-G needles in ex-vivo renal mass biopsy: a prospective, blinded study. Breda A, Treat EG, Haft-Candell L, Leppert JT, Harper JD, Said J, Raman S, Smith RB, Belldegrun AS, Schulam PG. BJU Int. 2010; 105 (7): 940-5
• Experience with 750 consecutive laparoscopic donor nephrectomies--is it time to use a standardized classification of complications? Harper JD, Breda A, Leppert JT, Veale JL, Gritsch HA, Schulam PG. J Urol. 2010; 183 (5): 1941-6
• Percutaneous cystolithotomy for calculi in reconstructed bladders: initial UCLA experience. Breda A, Mossanen M, Leppert J, Harper J, Schulam PG, Churchill B. J Urol. 2010; 183 (5): 1989-93
• Flexible ureteroscopy and laser lithotripsy for multiple unilateral intrarenal stones. Breda A, Ogunyemi O, Leppert JT, Schulam PG. Eur Urol. 2009; 55 (5): 1190-6
• Flexible ureteroscopy and laser lithotripsy for single intrarenal stones 2 cm or greater--is this the new frontier? Breda A, Ogunyemi O, Leppert JT, Lam JS, Schulam PG. J Urol. 2008; 179 (3): 981-4
• In vivo efficacy of laparoscopic assisted percutaneous renal cryotherapy: evidence based guidelines for the practicing urologist. Breda A, Lam JS, Riggs S, Leppert JT, Gui D, Said JW, Schulam PG, Belldegrun AS. J Urol. 2008; 179 (1): 333-7
• The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. Klatte T, Seligson DB, Leppert JT, Riggs SB, Yu H, Zomorodian N, Kabbinavar FF, Strieter RM, Belldegrun AS, Pantuck AJ. J Urol. 2008; 179 (1): 61-6
• Complications of laparoscopic renal surgery. Bergman J, Leppert JT, Breda A. Minerva Urol Nefrol. 2007; 59 (4): 417-23
• Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS. Clin Cancer Res. 2007; 13 (24): 7388-93
• Is the testis a chemo-privileged site? Is there a blood-testis barrier? Dave DS, Leppert JT, Rajfer J. Rev Urol. 2007; 9 (1): 28-32
• Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. Klatte T, Chung J, Leppert JT, Lam JS, Pantuck AJ, Figlin RA, Belldegrun AS. BJU Int. 2007; 99 (4): 821-4
• Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS, Figlin RA. Cancer. 2007; 109 (11): 2257-67
• The role of molecular markers in the staging of renal cell carcinoma. Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. BJU Int. 2007; 99 (5 Pt B): 1208-11
• The sensitivity of testosterone immunoassays and their role in monitoring antiandrogen therapy. Leppert JT, Lam JS, Butch AW, Belldegrun AS. Urol Oncol. 2006 Jul-Aug; 24 (4): 277-8
• Determining the prognosis of patients with renal cell carcinoma: is it time for a re-evaluation? Leppert JT, Pantuck AJ. Nat Clin Pract Urol. 2006; 3 (10): 510-1
• Implants of noninvasive papillary urothelial carcinoma in peritoneum and ileocolonic neobladder: support for "seed and soil" hypothesis of bladder recurrence. Herawi M, Leppert JT, Thomas GV, De Kernion JB, Epstein JI. Urology. 2006; 67 (4): 746-50
• Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A. Clin Cancer Res. 2006; 12 (13): 4018-26
• Prevention of bladder cancer: a review. Leppert JT, Shvarts O, Kawaoka K, Lieberman R, Belldegrun AS, Pantuck AJ. Eur Urol. 2006; 49 (2): 226-34
• RENCA/carbonic anhydrase-IX: a murine model of a carbonic anhydrase-IX-expressing renal cell carcinoma. Shvarts O, Janzen N, Lam JS, Leppert JT, Caliliw R, Figlin RA, Belldegrun AS, Zeng G. Urology. 2006; 68 (5): 1132-8
• Secondary hormonal therapy for advanced prostate cancer. Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS. J Urol. 2006; 175 (1): 27-34
• Significance of gene expression analysis of renal cell carcinoma. Leppert JT, Pantuck AJ. Expert Rev Anticancer Ther. 2006; 6 (2): 293-9
• Predicting response to interleukin-2 therapy among patients with renal cell carcinoma. Leppert JT, Lam JS, Belldegrun AS. J Immunother. 2005 Sep-Oct; 28 (5): 427-9
• Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. BJU Int. 2005; 96 (4): 483-8
• Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma. Leppert JT, Lam JS, Pantuck AJ, Figlin RA, Belldegrun AS. BJU Int. 2005; 96 (3): 281-5
• Novel approaches in the therapy of metastatic renal cell carcinoma. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. World J Urol. 2005; 23 (3): 202-12
• Open surgical management of renal cell carcinoma in the era of minimally invasive kidney surgery. Dave DS, Lam JS, Leppert JT, Belldegrun AS. BJU Int. 2005; 96 (9): 1268-74
• Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. J Urol. 2005; 174 (2): 466-72; discussion 472; quiz 801
• Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. J Urol. 2005; 173 (6): 1853-62
• Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Urology. 2005; 66 (5 Suppl): 1-9
• Surveillance following radical or partial nephrectomy for renal cell carcinoma. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Curr Urol Rep. 2005; 6 (1): 7-18
• Central neuronal loss and behavioral impairment in mice lacking neurotrophin receptor p75. Peterson DA, Dickinson-Anson HA, Leppert JT, Lee KF, Gage FH. J Comp Neurol. 1999; 404 (1): 1-20
• Basal forebrain neuronal loss in mice lacking neurotrophin receptor p75. Peterson DA, Leppert JT, Lee KF, Gage FH. Science. 1997; 277 (5327): 837-9